Clinical Trials Browser

Has results × Neoplasms × Fulvestrant × Clear all

Neoplasm Metastasis, Neoplasms

NCT03099174 2025-06-24

This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer

Phase 1 Completed

133 enrolled 26 charts

Breast

Breast Neoplasms, Neoplasms

NCT02437318 2025-02-13

SOLAR-1

Phase 3 Completed

572 enrolled 22 charts 1 FDA

BreastEndocrine

Breast Neoplasms, Neoplasms, Multiple Endocrine Neoplasia Type 1

NCT02964507 2024-08-29

Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Participants With Hormone Receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Advanced or Metastatic Breast Cancer

Phase 1 Terminated

124 enrolled 23 charts

Breast

Breast Neoplasms, Neoplasms

NCT01953926 2024-03-12

SUMMIT

Phase 2 Terminated

582 enrolled 27 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Neoplasms

NCT02422615 2023-11-30

MONALEESA-3

Phase 3 Completed

726 enrolled 17 charts 1 FDA

BreastEndocrine

Breast Diseases, Breast Neoplasms, Neoplasms, Neoplasms by Site, Multiple Endocrine Neoplasia Type 1

NCT02761694 2023-05-06

MK-4440-001

Phase 1 Terminated

78 enrolled 28 charts

Tumor-Agnostic

Neoplasms

NCT00313170 2020-01-06

FINDER II

Phase 2 Completed

144 enrolled 15 charts

Breast

Breast Neoplasms, Neoplasms

NCT02116803 2018-03-01

An Open Label Multi-center Extension Study to Evaluate Long-term Safety/ Tolerability of Dovitinib in Patients With Solid Tumors Who Continue to Receive Treatment With Dovitinib (TKI258) in Novartis-sponsored Single Agent Dovitinib Studies Which Fulfilled the Requirements for the Primary Objective

Phase 2/3 Completed

12 enrolled 6 charts

Tumor-Agnostic

Neoplasms

NCT00534417 2013-02-01

Phase II Trial of Capecitabine With Fulvestrant for Postmenopausal Women With Hormone Receptor Positive Metastatic Breast Cancer

Phase 2 Completed

41 enrolled 13 charts

Breast

Breast Neoplasms, Neoplasm Metastasis, Neoplasms

NCT00256698 2012-08-01

FACT

Phase 3 Completed

514 enrolled 13 charts

Breast

Breast Neoplasms, Neoplasms, Recurrence

NCT00357110 2010-12-21

@FAME

Phase 2 Completed

13 enrolled 7 charts

Breast

Breast Neoplasms, Neoplasms

Clinical Trials

FALCON

This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer

SOLAR-1

Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Participants With Hormone Receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Advanced or Metastatic Breast Cancer

SUMMIT

MONALEESA-3

MK-4440-001

FINDER II

An Open Label Multi-center Extension Study to Evaluate Long-term Safety/ Tolerability of Dovitinib in Patients With Solid Tumors Who Continue to Receive Treatment With Dovitinib (TKI258) in Novartis-sponsored Single Agent Dovitinib Studies Which Fulfilled the Requirements for the Primary Objective

Phase II Trial of Capecitabine With Fulvestrant for Postmenopausal Women With Hormone Receptor Positive Metastatic Breast Cancer

FACT

@FAME